Literature DB >> 28188790

The role of ELK3 to regulate peritumoral lymphangiogenesis and VEGF-C production in triple negative breast cancer cells.

Nuri Oh1, Ji-In Park1, Ji-Hoon Park1, Kwang-Soo Kim1, Dong Ryul Lee1, Kyung-Soon Park2.   

Abstract

Tumor-induced lymphangiogenesis, a major conduit for cancer cell dissemination from the primary tumor site to lymph nodes and beyond, eventually leads to metastasis in cancer patients. Given the recent evidence revealing that the suppression of ELK3 inhibits the metastasis of triple-negative breast cancer cells, we aimed to study the underlying mechanism of impaired metastasis in ELK3-suppressed MDA-MB-231 cells (ELK3 KD) with regard to lymphangiogenesis. We found that the secretome of ELK3 KD cells inhibited tube formation, whereas it promoted the migration and invasion of lymphatic endothelial cells (LECs) in vitro. In vivo analysis revealed that peritumoral lymphatic vessels were not developed around the xenografted tumors of ELK3 KD. We further revealed that the suppression of NF-κB signaling in ELK3 KD was the primary cause of the reduced VEGFC expression. Taken together, we suggest that ELK3 is an upstream regulator of the NF-κB signaling pathway, the inhibition of which leads to the suppression of peritumoral lymphatic vessel development, possibly due to a low VEGFC expression.
Copyright © 2017. Published by Elsevier Inc.

Entities:  

Keywords:  CXCL12; Elk3; Lymphangiogenesis; MDA-MB-231; NF-κB; VEGFC

Mesh:

Substances:

Year:  2017        PMID: 28188790     DOI: 10.1016/j.bbrc.2017.02.030

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  7 in total

1.  [Expression characteristics and functional analysis of ELK3 in gastric cancer].

Authors:  L Zhou; Y Wu; L Xin
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2021-08-31

2.  Cytokines secreted by stromal cells in TNBC microenvironment as potential targets for cancer therapy.

Authors:  Marie K Malone; Karly Smrekar; Sunju Park; Brianna Blakely; Alec Walter; Nicholas Nasta; Jay Park; Michael Considine; Ludmila V Danilova; Niranjan B Pandey; Elana J Fertig; Aleksander S Popel; Kideok Jin
Journal:  Cancer Biol Ther       Date:  2020-03-26       Impact factor: 4.742

3.  LINC01106 post-transcriptionally regulates ELK3 and HOXD8 to promote bladder cancer progression.

Authors:  Liwei Meng; Zhaoquan Xing; Zhaoxin Guo; Zhaoxu Liu
Journal:  Cell Death Dis       Date:  2020-12-12       Impact factor: 8.469

4.  Molecular and clinical features of a potential immunotherapy target ELK3 in glioma.

Authors:  Hao Xu; Li Zhang; Jin Gao; Jiajing Wang; Yihao Wang; Dongdong Xiao; Songshan Chai
Journal:  Medicine (Baltimore)       Date:  2022-07-29       Impact factor: 1.817

5.  ELK3 modulates the antitumor efficacy of natural killer cells against triple negative breast cancer by regulating mitochondrial dynamics.

Authors:  Joo Dong Park; Kwang-Soo Kim; Seung Hee Choi; Gae Hoon Jo; Jin-Ho Choi; Si-Won Park; Eun-Su Ko; Minwook Lee; Dae-Keum Lee; Hye Jung Jang; Sohyun Hwang; Hae-Yun Jung; Kyung-Soon Park
Journal:  J Immunother Cancer       Date:  2022-07       Impact factor: 12.469

6.  Prognostic signature composed of transcription factors accurately predicts the prognosis of gastric cancer patients.

Authors:  Liqiang Zhou; Zhiqing Chen; You Wu; Hao Lu; Lin Xin
Journal:  Cancer Cell Int       Date:  2021-07-07       Impact factor: 5.722

7.  Tumor necrosis factor superfamily 15 promotes lymphatic metastasis via upregulation of vascular endothelial growth factor-C in a mouse model of lung cancer.

Authors:  Tingting Qin; Dingzhi Huang; Zhujun Liu; Xiaoling Zhang; Yanan Jia; Cory J Xian; Kai Li
Journal:  Cancer Sci       Date:  2018-07-20       Impact factor: 6.716

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.